港股异动 | 康方生物(09926)早盘涨近8% 全球首创的三特异性抗体新药AK150进入临床

智通财经
Mar 10

智通财经APP获悉,康方生物(09926)早盘涨近8%,截至发稿,涨7.33%,报111.3港元,成交额2.76亿港元。

消息面上,康方生物全球首创的三特异性抗体新药AK150(ILT2/ILT4/CSF1R三抗)获得国家药品监督管理局药品审评中心临床试验默示许可批准,开展用于治疗晚期恶性实体瘤的临床试验。

公开资料显示,AK150是全球唯一在研的ILT2/ILT4/CSF1R三抗,也是康方生物首个进入临床阶段的三抗新药。AK150是康方生物基于领先的AI制药研发技术平台和Tetrabody多抗技术平台而开发的全球首创新药,是公司在多特异性抗体技术领域强劲实力的又一次见证。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10